STOCK TITAN

Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Tags

Poseida Therapeutics (PSTX) hosted a virtual R&D Day showcasing its allogeneic CAR-T therapy pipeline across hematologic malignancies, solid tumors, and autoimmune diseases. The company highlighted recent Phase 1 data for P-BCMA-ALLO1 and new preclinical findings for multiple programs. Key updates include P-CD19CD20-ALLO1's progress in B-cell malignancies, P-CD70-ALLO1's potential in AML, and P-BCMACD19-ALLO1's promising results in both autoimmune diseases and oncology. The company also presented innovative strategies for solid tumors through programs like P-MUC1C-ALLO1 and P-PSMA-ALLO1, leveraging their proprietary non-viral technology platform and TSCM-rich CAR-T approach.

Poseida Therapeutics (PSTX) ha ospitato un evento virtuale di R&D per presentare il suo pipeline di terapie CAR-T allogeniche in malignità ematologiche, tumori solidi e malattie autoimmuni. L'azienda ha evidenziato i recenti dati della Fase 1 per P-BCMA-ALLO1 e nuove scoperte precliniche per diversi programmi. Aggiornamenti chiave includono i progressi di P-CD19CD20-ALLO1 nelle malignità delle cellule B, il potenziale di P-CD70-ALLO1 nella leucemia mieloide acuta (AML) e i risultati promettenti di P-BCMACD19-ALLO1 sia nelle malattie autoimmuni che in oncologia. L'azienda ha inoltre presentato strategie innovative per i tumori solidi attraverso programmi come P-MUC1C-ALLO1 e P-PSMA-ALLO1, sfruttando la loro piattaforma tecnologica non virale proprietaria e l'approccio CAR-T ricco di TSCM.

Poseida Therapeutics (PSTX) organizó un evento virtual de I+D para mostrar su pipeline de terapia CAR-T alogénica en neoplasias hematológicas, tumores sólidos y enfermedades autoinmunitarias. La compañía destacó los recientes datos de la Fase 1 para P-BCMA-ALLO1 y nuevos hallazgos preclínicos para múltiples programas. Las actualizaciones clave incluyen el progreso de P-CD19CD20-ALLO1 en malignidades de células B, el potencial de P-CD70-ALLO1 en leucemia mieloide aguda (AML) y los resultados prometedores de P-BCMACD19-ALLO1 tanto en enfermedades autoinmunitarias como en oncología. La compañía también presentó estrategias innovadoras para tumores sólidos a través de programas como P-MUC1C-ALLO1 y P-PSMA-ALLO1, aprovechando su plataforma tecnológica no viral y el enfoque CAR-T rico en TSCM.

포세이다 테라퓨틱스( PSTX)는 혈액 악성 종양, 고형 종양 및 자가면역 질환에 대한 자가면역 CAR-T 치료 파이프라인을 소개하는 가상 연구 개발(R&D) 데이를 개최했습니다. 회사는 P-BCMA-ALLO1에 대한 최근 1상 데이터를 강조하고 여러 프로그램에 대한 새로운 전임상 발견을 공유했습니다. 주요 업데이트에는 B세포 악성 종양에서의 P-CD19CD20-ALLO1의 진행 상황, AML에서의 P-CD70-ALLO1의 잠재력, 그리고 자가면역 질환 및 종양학에서의 P-BCMACD19-ALLO1의 유망한 결과가 포함됩니다. 또한 회사는 P-MUC1C-ALLO1 및 P-PSMA-ALLO1와 같은 프로그램을 통해 고형 종양에 대한 혁신적인 전략을 제시했으며, 자사 독점의 비바이럴 기술 플랫폼과 TSCM이 풍부한 CAR-T 접근 방식을 활용했습니다.

Poseida Therapeutics (PSTX) a organisé une journée virtuelle de R&D pour présenter son pipeline de thérapies CAR-T allogéniques dans les malignités hématologiques, les tumeurs solides et les maladies auto-immunes. L'entreprise a souligné les données récentes de la Phase 1 pour P-BCMA-ALLO1 et de nouvelles découvertes précliniques pour plusieurs programmes. Les mises à jour clés incluent les progrès de P-CD19CD20-ALLO1 dans les malignités des cellules B, le potentiel de P-CD70-ALLO1 dans la leucémie myéloïde aiguë (LMA) et les résultats prometteurs de P-BCMACD19-ALLO1 tant dans les maladies auto-immunes qu'en oncologie. L'entreprise a également présenté des stratégies innovantes pour les tumeurs solides à travers des programmes comme P-MUC1C-ALLO1 et P-PSMA-ALLO1, capitalisant sur leur plateforme technologique non virale propriétaire et leur approche CAR-T riche en TSCM.

Poseida Therapeutics (PSTX) veranstaltete einen virtuellen F&E-Tag, um seine allogenen CAR-T-Therapien in hämatologischen Malignitäten, soliden Tumoren und Autoimmunerkrankungen vorzustellen. Das Unternehmen hob die aktuellen Phase-1-Daten für P-BCMA-ALLO1 sowie neue präklinische Ergebnisse für mehrere Programme hervor. Zu den wichtigsten Neuigkeiten gehören der Fortschritt von P-CD19CD20-ALLO1 bei B-Zell-Malignitäten, das Potenzial von P-CD70-ALLO1 bei AML und die vielversprechenden Ergebnisse von P-BCMACD19-ALLO1 sowohl bei Autoimmunerkrankungen als auch in der Onkologie. Das Unternehmen präsentierte zudem innovative Strategien für solide Tumoren durch Programme wie P-MUC1C-ALLO1 und P-PSMA-ALLO1 und nutzte dabei ihre proprietäre nicht-virale Technologieplattform und den CAR-T-Ansatz, der reich an TSCM ist.

Positive
  • Phase 1 clinical trial enrollment ongoing for P-CD19CD20-ALLO1 with data expected in 2025
  • P-MUC1C-ALLO1 showed 42% decrease in lymph node size with prolonged stable disease in a patient case
  • Collaboration with Roche strengthens pipeline development
  • In-house GMP manufacturing facility capable of producing over 100 doses per batch
  • Demonstrated ability to target mutations linked to relapse in multiple myeloma patients
Negative
  • No approved CAR-T therapies for solid tumors yet
  • Multiple clinical trials still in early phases
  • Complex manufacturing process requiring optimization

Insights

The R&D Day presentation reveals significant progress in Poseida's allogeneic CAR-T pipeline, particularly highlighting three key areas: hematologic malignancies, solid tumors and autoimmune diseases. The company's proprietary non-viral technology platform, featuring TSCM-rich CAR-T cells, demonstrates promising potential across multiple indications.

Key pipeline developments include:

  • P-BCMA-ALLO1 for multiple myeloma showing effectiveness against known resistance mutations
  • P-CD19CD20-ALLO1 dual CAR-T program with strong preclinical data
  • P-BCMACD19-ALLO1 showing potential in both autoimmune diseases and oncology
  • P-MUC1C-ALLO1 for solid tumors with notable clinical case study results

The company's in-house manufacturing capabilities and strategic collaborations with Roche and Astellas strengthen their competitive position. Their technology platform's ability to preserve TSCM cells, which are important for CAR-T therapy success, sets them apart in the field.

The manufacturing capabilities highlighted in this presentation are particularly noteworthy. The company's wholly-owned GMP facility demonstrates several competitive advantages:

  • Consistent high-purity apheresis across different donors
  • Scalable manufacturing with 100+ doses per batch potential
  • Proprietary Booster Molecule enabling cost-effective production

The planned manufacturing enhancements, including AI-assisted donor screening and improved electroporation, could further optimize production efficiency and reduce costs. This vertical integration of manufacturing is important for maintaining quality control and potentially improving margins in the cell therapy space.

Emerging leadership in allogeneic CAR-T for hematologic malignancies demonstrated by recent P-BCMA-ALLO1 Phase 1 data and new preclinical findings for P-CD19CD20-ALLO1 and P-CD70-ALLO1

Latest preclinical data on P-BCMACD19-ALLO1 demonstrates its potential as a next-generation allogeneic TSCM-rich CAR-T for both autoimmune diseases and oncology

Advancing innovative strategies to overcome the unique challenges of applying CAR-T to solid tumors

Virtual R&D Day featuring partner Astellas Pharma and Poseida's leadership and scientific teams to be held today at 10:00am ET / 7:00am PT

SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced plans to share progress across its clinical- and earlier-stage pipeline of differentiated T stem cell memory cells (TSCM)-rich allogeneic CAR-T therapies in oncology and autoimmune diseases during a virtual R&D Day to be held today at 10:00am ET / 7:00am PT.

"We believe Poseida is well positioned to be a cell therapy leader based on the unique capabilities of our proprietary non-viral technology platform and our allogeneic TSCM-rich CAR-T approach," said Kristin Yarema, Ph.D., President and Chief Executive Officer of Poseida Therapeutics. "We are organizing our pipeline around three pillars – hematologic malignancies, solid tumors and autoimmune diseases – with multiple candidates in each that give us a wide range of opportunities. In the emerging field of cell therapy for autoimmune diseases, we are optimistic that our platform can build upon the early success seen with autologous CAR-T by offering an off-the-shelf option that would expand accessibility and address the potential drivers of relapse with more complete B cell depletion."

"Building on the advantages of our non-viral allogeneic TSCM-rich approach, we are implementing several advanced technologies aimed at bringing the benefits of CAR-T therapy to patients with solid tumors," said Devon J. Shedlock, Ph.D., Chief Scientific Officer, Cell Therapy at Poseida Therapeutics. "This includes our collaboration with Astellas, which brings together the unique technologies from both companies to create a new class of CAR-T, convertibleCARs®, which employs multi-antigen targeting and other enhancements to improve CAR-T potency and persistence."

The event will feature presentations by members of Poseida's management team and will include a fireside chat with Peter Sandor, M.D., EVP and Head of Corporate Strategy at Astellas Pharma, that will cover the research collaboration and license agreement between Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas, "Xyphos") and Poseida to develop novel convertibleCAR® programs by combining the innovative cell therapy platforms from each of the companies. Poseida management will participate in a Q&A session at the end of the program.

Cell therapy technology platform: Poseida has built a full set of non-viral capabilities to design and develop allogeneic, TSCM-rich CAR-T therapies. TSCM cells are considered ideal for CAR-T therapy because they are long-lived, multi-potent and self-replicating, with the potential for an improved safety and efficacy profile. This compares to other approaches, which either use a different cell type or drive T cell differentiation (and therefore less stemness) as part of the process to manufacture the CAR-T cells. The key elements of Poseida's approach include:

  • Non-viral, transposon-based gene insertion system preferentially integrates genes into naïve and TSCM cells, with a high cargo capacity that allows for adding multiple genes to enhance functionality and add safety features
  • Cas-CLOVER gene editing system preserves the TSCM cell type and operates effectively in resting T cells. It offers approximately 25-times greater fidelity than CRISPR-Cas9, supporting improved safety and quality
  • Wholly-owned, onsite GMP manufacturing facility positioned to serve discovery through commercial needs across the Company's pipeline. The Company's Booster Molecule has enabled a scalable, lower cost manufacturing approach with the proven ability to generate cell yield up to over 100 doses per batch

Emerging leadership in allogeneic CAR-T for hematologic malignancies: Poseida will provide an overview of recently reported interim Phase 1 results for P-BCMA-ALLO1, its lead CAR-T program targeting BCMA for the treatment of multiple myeloma. New preclinical data suggest that P-BCMA-ALLO1 effectively targets mutations that are known to arise in patients with relapse after prior anti-BCMA therapies. P-BCMA-ALLO1 is part of Poseida's collaboration with Roche and is currently enrolling a Phase 1b dose expansion study, which will be outlined in the presentation. In addition, the Company will highlight its emerging pipeline programs for hematologic malignancies:

  • P-CD19CD20-ALLO1 is the Company's first dual CAR-T program targeting CD19 and CD20 for the treatment of B-cell malignancies in collaboration with Roche. New preclinical data demonstrate that P-CD19CD20-ALLO1 delivers high in vitro potency and strong in vivo antitumor activity for either CD19 or CD20 single-positive target cells, as well as double-positive targets. A Phase 1 clinical trial is enrolling patients with selected B-cell malignancies, with initial clinical data anticipated in 2025. Additional information about the trial is available at www.clinicaltrials.gov using identifier: NCT06014762.
    • Beyond hematologic malignancies, preclinical data also demonstrate robust in vitro activity against patient-derived B cells across multiple autoimmune diseases
  • P-CD70-ALLO1 is a preclinical program targeting CD70 for the treatment of diseases including acute myeloid leukemia (AML). New preclinical data demonstrate P-CD70-ALLO1's robust anti-AML effect, with no toxicity to hematopoietic stem cells. In addition, there is a growing body of clinical and preclinical evidence that targeting CD70 with cell therapy may be an effective treatment for solid tumors. Roche has an option to add this as a potential new program to the collaboration

Expanding allogeneic TSCM-rich CAR-T to autoimmune disease: Poseida's cell therapy technology platform has the potential to create CAR-T therapies designed to address the challenges with existing emerging approaches to applying cell therapy to autoimmune disease, including autologous CAR-T, in vivo CAR-T and T cell engagers. The Company's lead program for autoimmune disease is P-BCMACD19-ALLO1, a dual CAR-T targeting BCMA and CD19. New preclinical data demonstrate P-BCMACD19-ALLO1's potential in both autoimmune disease and oncology:

  • Demonstrated robust in vitro killing of patient-derived B cells across multiple autoimmune diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and multiple sclerosis (MS), which collectively affect more than 5 million people in the U.S.
  • Achieved dose-dependent depletion of primary human B cells in a humanized mouse model generated with human CD34+ cells
  • Effectively eliminated primary human CD81+CD19+ multiple myeloma progenitor cells from patient bone marrow samples, addressing cells associated with relapse where BCMA-only targeted therapies were ineffective
  • Demonstrated ability of P-BCMACD19-ALLO1 and P-BCMA-ALLO1 to kill tumor cells expressing known mutant forms of BCMA, which are linked to relapse in patients treated with autologous CAR-T and bispecific T cell engager therapies directed at BCMA

Poseida is conducting IND-enabling studies for P-BCMACD19-ALLO1 and plans to file one or more INDs for an autoimmune disease indication with the U.S. Food and Drug Administration.

Addressing historical barriers for CAR-T in solid tumors through a broad array of bold, innovative technologies enabled by the Company's platform: There are currently no CAR-T therapies approved for solid tumors, with several key factors believed to be roadblocks: 1) antigen heterogeneity; 2) differing lymphodepletion needs compared to hematologic malignancies to enable CAR-T cell engraftment, tracking, and infiltration; 3) on-target off-tumor toxicity; and 4) hostile tumor microenvironment. Poseida is approaching these challenges with a suite of technologies across multiple solid tumor programs:

  • P-MUC1C-ALLO1 is Poseida's lead solid tumor CAR-T program targeting MUC1-C, a membrane protein overexpressed in many epithelial cancers. A Phase 1 clinical trial is enrolling patients with treatment-resistant breast, ovarian, colorectal and other solid tumors, with ongoing exploration of P-MUC1C-ALLO1 dosing and lymphodepletion regimens. A clinical data update is planned for the European Society for Medical Oncology Immuno-Oncology Congress 2024 (ESMO-IO) taking place in Geneva December 11-13, 2024. A patient case study from the Phase 1 trial demonstrated a 42% decrease in paraesophageal lymph node size with prolonged stable disease for nearly a year in a heavily pretreated appendiceal carcinoma patient. New preclinical data suggest adding low-dose methotrexate to standard lymphodepletion may enhance CAR-T expansion and persistence
  • P-PSMA-ALLO1 is a preclinical program targeting PSMA for prostate cancer. In preclinical models, P-PSMA-ALLO1's dual CAR format showed superior in vivo anti-tumor activity and cytotoxicity compared to single and tandem binder CAR-Ts
  • Poseida and Xyphos are developing allogeneic convertibleCARs® for solid tumors, combining Poseida's allogeneic CAR-TSCM platform with Xyphos' ACCEL™ technology to create controlled, long lasting, and highly active CAR-T therapies. New preclinical data shows positive results for an allogeneic convertibleCAR-TSCM targeting universal inert natural killer group 2 member D receptor (iNKG2D), paired with a solid tumor antigen-targeting MicAbody™. Poseida and Xyphos are working to optimize this convertibleCAR® and MicAbody™ pairing, and other platform technologies designed to maximize potency and persistence
  • Poseida will highlight its allogeneic CAR-TCR-T cells to address antigen heterogeneity in solid tumors. The Company recently presented new preclinical data demonstrating enhanced potency to better target solid tumors at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. Preclinical data highlight the potential of a combination of CAR-TCR-T cell treatment followed by a T cell engager (TCE). In this model, MUC1C-CAR and NY-ESO-1-TCR T cells effectively controlled a primary tumor (MUC1C+/NY-ESO-1+/CD70-), and later were reactivated and re-directed by a CD70 TCE to control challenge by a secondary tumor (MUC1C-/NY-ESO-1-/CD70+)

In-house manufacturing to support Poseida's broad cell therapy pipeline: the Company will highlight the capabilities of its GMP facility and team, including:

  • New data demonstrated high-purity apheresis across different healthy donors, with consistency in CAR-T manufacturing (cellular expansion, gene editing, final phenotype) across collections from the same donor
  • Future manufacturing platform enhancement opportunities including AI-assisted donor screening to improve efficiency; improving electroporation unit operations to improve gene editing efficiency and subsequent cell health; and leveraging dynamic bioreactor environments to increase yields

Video Webcast and Replay
This virtual event and access to the live webcast is available through the following registration link: https://wsw.com/webcast/cc/pstx7/1467684.

Registration for this virtual event and access to a replay of the live webcast will be available on the Investors & Media section of www.poseida.com. A replay of the webcast will be available for approximately 90 days following the presentation.

About Poseida Therapeutics, Inc.
Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure. The Company's pipeline includes investigational allogeneic CAR-T cell therapies for hematologic cancers, autoimmune diseases, and solid tumors, as well as investigational in vivo genetic medicines that address patient populations with high unmet medical need. The Company's approach is based on its proprietary genetic editing platforms, including its non-viral transposon-based DNA delivery system, Cas-CLOVER™ Site-Specific Gene Editing System, Booster Molecule and nanoparticle gene delivery technologies, as well as in-house GMP cell therapy manufacturing. The Company has formed strategic collaborations with Roche and Astellas to unlock the promise of cell therapies for cancer patients. Learn more at www.poseida.com and connect with Poseida on X and LinkedIn.

Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, expected plans with respect to clinical trials, including timing of clinical data updates; anticipated timelines and milestones with respect to the Company's development programs and manufacturing activities and capabilities; the potential capabilities and benefits of the Company's technology platforms and product candidates, including the efficacy and safety profile of such product candidates; the quotes from Drs. Yarema and Shedlock; and the Company's plans and strategy with respect to developing its technologies and product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the fact that interim data from the Company's clinical trials may change as more patient data become available and remain subject to audit and verification procedures that could result in material differences from the final data; the Company's reliance on third parties for various aspects of its business; risks and uncertainties associated with development and regulatory approval of novel product candidates in the biopharmaceutical industry; the Company's ability to retain key scientific or management personnel; the Company's ongoing and planned clinical trials; risks and uncertainties associated with conducting clinical trials; competition in the Company's target markets; whether any of the Company's product candidates will be shown to be effective or safe; the Company's ability to finance continued operations; the fact that the Company will have limited control over the efforts and resources that its collaborators devote to advancing development programs under their respective collaboration agreements; the fact that the Company may not receive the potential fees, reimbursements and payments under the collaboration agreements; the ability of the Company's collaborators to early terminate the collaboration, such that the Company may not fully realize the benefits of the collaborations; and the other risks and uncertainties described in the Company's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-hosts-cell-therapy-rd-day-highlighting-its-innovative-clinical-and-preclinical-pipeline-302305111.html

SOURCE Poseida Therapeutics, Inc.

FAQ

What are the main therapeutic areas for Poseida's (PSTX) CAR-T pipeline?

Poseida's CAR-T pipeline focuses on three main areas: hematologic malignancies, solid tumors, and autoimmune diseases.

When will Poseida (PSTX) release clinical data for P-CD19CD20-ALLO1?

Initial clinical data for P-CD19CD20-ALLO1 is anticipated in 2025.

What results did Poseida's (PSTX) P-MUC1C-ALLO1 show in the patient case study?

P-MUC1C-ALLO1 demonstrated a 42% decrease in paraesophageal lymph node size with prolonged stable disease for nearly a year in a heavily pretreated appendiceal carcinoma patient.

How many doses can Poseida's (PSTX) manufacturing facility produce per batch?

Poseida's manufacturing facility can generate cell yield up to over 100 doses per batch.

Poseida Therapeutics, Inc.

NASDAQ:PSTX

PSTX Rankings

PSTX Latest News

PSTX Stock Data

267.54M
70.29M
27.64%
55.75%
4.52%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SAN DIEGO